$86.30
0.190.22%
al cierre: -
$86.30
N/A
After hour: Nov 14, 4:00 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Edwards Lifesciences Corp tiene un precio objetivo de consenso de $90.26 basado en las calificaciones de 21 analistas. El máximo es $104, emitido por Goldman Sachs el octubre 31, 2025. El mínimo es $70, emitido por TD Cowen el julio 25, 2024. Las 3 calificaciones de analistas más recientes fueron publicadas por Truist Securities, Canaccord Genuity y Barclays el noviembre 3, 2025, noviembre 3, 2025 y octubre 31, 2025, respectivamente. Con un precio objetivo promedio de $91 entre Truist Securities, Canaccord Genuity y Barclays, hay una 5.45% upside implícita para Edwards Lifesciences Corp según estas calificaciones más recientes de analistas.
Firmas de analistas que realizan recomendaciones1
Truist Securities
Canaccord Genuity
Barclays
Citigroup
JP Morgan
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Edwards Lifesciences
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/03/2025 | 4.29% | Truist Securities | $87 → $90 | Maintains | Hold | |||
11/03/2025 | -2.67% | Canaccord Genuity | $81 → $84 | Maintains | Hold | |||
10/31/2025 | 14.72% | Barclays | $95 → $99 | Maintains | Overweight | |||
10/31/2025 | 11.24% | Citigroup | $95 → $96 | Maintains | Buy | |||
10/31/2025 | 4.29% | JP Morgan | $85 → $90 | Maintains | Neutral | |||
10/31/2025 | 20.51% | Goldman Sachs | $94 → $104 | Maintains | Buy | |||
10/31/2025 | 10.08% | Piper Sandler | $90 → $95 | Reiterates | Overweight → Overweight | |||
10/31/2025 | 10.08% | RBC Capital | $89 → $95 | Maintains | Outperform | |||
10/31/2025 | 10.08% | Stifel | $85 → $95 | Maintains | Buy | |||
10/31/2025 | 6.6% | Evercore ISI Group | $88 → $92 | Maintains | Outperform | |||
10/31/2025 | 15.87% | Mizuho | $90 → $100 | Maintains | Outperform | |||
10/29/2025 | — | Wolfe Research | — | Upgrade | Underperform → Peer Perform | |||
10/29/2025 | 13.56% | Jefferies | $80 → $98 | Upgrade | Hold → Buy | |||
10/28/2025 | 0.81% | Truist Securities | $82 → $87 | Maintains | Hold | |||
10/08/2025 | — | Oppenheimer | — | Downgrade | Outperform → Perform | |||
10/07/2025 | 1.97% | Evercore ISI Group | $80 → $88 | Upgrade | In-Line → Outperform | |||
09/22/2025 | -1.51% | Stifel | $95 → $85 | Maintains | Buy | |||
08/07/2025 | 1.97% | Wells Fargo | $84 → $88 | Maintains | Overweight | |||
07/25/2025 | -1.51% | JP Morgan | $80 → $85 | Maintains | Neutral | |||
07/25/2025 | -6.14% | Canaccord Genuity | $75 → $81 | Maintains | Hold | |||
07/25/2025 | 10.08% | Mizuho | $87 → $95 | Maintains | Outperform | |||
07/25/2025 | -4.98% | Truist Securities | $81 → $82 | Maintains | Hold | |||
07/25/2025 | 10.08% | Stifel | $90 → $95 | Maintains | Buy | |||
07/25/2025 | 10.08% | Barclays | $90 → $95 | Maintains | Overweight | |||
07/25/2025 | 4.29% | Piper Sandler | $83 → $90 | Maintains | Overweight | |||
07/25/2025 | 3.13% | RBC Capital | $85 → $89 | Maintains | Outperform | |||
07/25/2025 | -2.67% | Wells Fargo | $80 → $84 | Maintains | Overweight | |||
07/25/2025 | -7.3% | Evercore ISI Group | $77 → $80 | Maintains | In-Line | |||
07/25/2025 | 8.92% | Deutsche Bank | $85 → $94 | Maintains | Buy | |||
07/25/2025 | -8.46% | Baird | $78 → $79 | Maintains | Neutral | |||
07/16/2025 | 0.81% | Mizuho | $85 → $87 | Maintains | Outperform | |||
07/15/2025 | -6.14% | Morgan Stanley | $75 → $81 | Maintains | Equal-Weight | |||
07/08/2025 | -10.78% | Evercore ISI Group | $73 → $77 | Maintains | In-Line | |||
05/22/2025 | 10.08% | Citigroup | $84 → $95 | Maintains | Buy | |||
05/13/2025 | -3.82% | Piper Sandler | $80 → $83 | Maintains | Overweight | |||
04/25/2025 | -13.09% | Canaccord Genuity | $71 → $75 | Maintains | Hold | |||
04/24/2025 | -7.3% | Piper Sandler | $73 → $80 | Upgrade | Neutral → Overweight | |||
04/24/2025 | -13.09% | Baird | $72 → $75 | Maintains | Neutral | |||
04/11/2025 | -13.09% | Truist Securities | $78 → $75 | Maintains | Hold | |||
02/13/2025 | 4.29% | Barclays | $88 → $90 | Maintains | Overweight | |||
02/13/2025 | -17.73% | Canaccord Genuity | $68 → $71 | Maintains | Hold | |||
02/12/2025 | -1.51% | RBC Capital | $85 → $85 | Reiterates | Outperform → Outperform | |||
02/12/2025 | -15.41% | Piper Sandler | $70 → $73 | Maintains | Neutral | |||
02/12/2025 | -15.41% | Evercore ISI Group | $75 → $73 | Maintains | In-Line | |||
02/12/2025 | -13.09% | Morgan Stanley | $70 → $75 | Maintains | Equal-Weight | |||
01/30/2025 | 4.29% | Stifel | $75 → $90 | Upgrade | Hold → Buy | |||
01/16/2025 | -30.48% | Wolfe Research | $60 → $60 | Downgrade | Peer Perform → Underperform | |||
12/16/2024 | 4.29% | B of A Securities | $82 → $90 | Upgrade | Neutral → Buy | |||
12/11/2024 | -3.82% | Citigroup | $81 → $83 | Maintains | Buy | |||
12/05/2024 | 4.29% | Goldman Sachs | $81 → $90 | Maintains | Buy | |||
12/05/2024 | -9.62% | Truist Securities | $70 → $78 | Reiterates | Hold → Hold | |||
12/05/2024 | -13.09% | Stifel | $70 → $75 | Maintains | Hold | |||
12/05/2024 | -1.51% | RBC Capital | $80 → $85 | Maintains | Outperform | |||
12/05/2024 | -21.21% | Canaccord Genuity | $63 → $68 | Maintains | Hold | |||
12/02/2024 | 1.97% | Barclays | $85 → $88 | Maintains | Overweight | |||
11/27/2024 | -7.3% | RBC Capital | $75 → $80 | Maintains | Outperform | |||
10/25/2024 | -27% | Canaccord Genuity | $66 → $63 | Maintains | Hold | |||
10/25/2024 | -9.62% | JP Morgan | $72 → $78 | Maintains | Neutral | |||
10/25/2024 | -18.89% | Piper Sandler | $73 → $70 | Maintains | Neutral | |||
10/25/2024 | -18.89% | Truist Securities | $71 → $70 | Maintains | Hold | |||
10/25/2024 | -21.21% | Baird | $73 → $68 | Maintains | Neutral | |||
10/11/2024 | -18.89% | Morgan Stanley | → $70 | Reinstates | → Equal-Weight | |||
10/08/2024 | -13.09% | RBC Capital | $85 → $75 | Maintains | Outperform | |||
10/07/2024 | -23.52% | Canaccord Genuity | $77 → $66 | Maintains | Hold | |||
10/01/2024 | -18.89% | Evercore ISI Group | $76 → $70 | Maintains | In-Line | |||
10/01/2024 | -10.78% | Citigroup | $83 → $77 | Maintains | Buy | |||
09/18/2024 | -18.89% | Jefferies | $85 → $70 | Downgrade | Buy → Hold | |||
09/13/2024 | -17.73% | Truist Securities | $82 → $71 | Maintains | Hold | |||
09/12/2024 | 4.29% | Oppenheimer | $90 → $90 | Maintains | Outperform | |||
09/10/2024 | -13.09% | UBS | $90 → $75 | Maintains | Neutral | |||
09/09/2024 | -7.3% | Barclays | $90 → $80 | Maintains | Overweight | |||
09/09/2024 | -7.3% | Wells Fargo | $90 → $80 | Maintains | Overweight | |||
07/29/2024 | — | Wolfe Research | — | Upgrade | Underperform → Peer Perform | |||
07/26/2024 | 4.29% | Barclays | $101 → $90 | Maintains | Overweight | |||
07/26/2024 | 5.45% | Goldman Sachs | $107 → $91 | Maintains | Buy | |||
07/25/2024 | -18.89% | TD Cowen | $100 → $70 | Downgrade | Buy → Hold | |||
07/25/2024 | 4.29% | Wells Fargo | $99 → $90 | Maintains | Overweight | |||
07/25/2024 | -11.94% | Evercore ISI Group | $91 → $76 | Maintains | In-Line | |||
07/25/2024 | -1.51% | Deutsche Bank | $103 → $85 | Maintains | Buy | |||
07/25/2024 | -1.51% | RBC Capital | $101 → $85 | Maintains | Outperform | |||
07/25/2024 | -4.98% | Truist Securities | $110 → $82 | Downgrade | Buy → Hold | |||
07/25/2024 | -18.89% | Stifel | $85 → $70 | Maintains | Hold | |||
07/25/2024 | 4.29% | Oppenheimer | $100 → $90 | Maintains | Outperform | |||
07/25/2024 | -10.78% | Canaccord Genuity | $85 → $77 | Maintains | Hold | |||
07/25/2024 | -15.41% | Piper Sandler | $88 → $73 | Maintains | Neutral | |||
07/25/2024 | -13.09% | B of A Securities | $105 → $75 | Downgrade | Buy → Neutral | |||
07/25/2024 | -16.57% | JP Morgan | $105 → $72 | Downgrade | Overweight → Neutral | |||
07/25/2024 | -18.89% | Baird | $102 → $70 | Downgrade | Outperform → Neutral | |||
07/16/2024 | 27.46% | Truist Securities | $105 → $110 | Maintains | Buy | |||
07/10/2024 | 22.83% | Citigroup | $105 → $106 | Maintains | Buy | |||
07/02/2024 | 5.45% | Evercore ISI Group | $89 → $91 | Maintains | In-Line | |||
05/30/2024 | 23.99% | Goldman Sachs | → $107 | Initiates | → Buy | |||
05/22/2024 | 21.67% | Citigroup | $98 → $105 | Upgrade | Neutral → Buy | |||
05/14/2024 | 19.35% | Deutsche Bank | $86 → $103 | Upgrade | Hold → Buy | |||
05/07/2024 | 17.03% | Barclays | $100 → $101 | Maintains | Overweight | |||
04/26/2024 | -1.51% | Canaccord Genuity | $86 → $85 | Maintains | Hold | |||
04/26/2024 | 14.72% | Wells Fargo | $94 → $99 | Maintains | Overweight | |||
04/26/2024 | 3.13% | Evercore ISI Group | $92 → $89 | Maintains | In-Line | |||
04/26/2024 | -1.51% | Stifel | $83 → $85 | Maintains | Hold | |||
04/26/2024 | 1.97% | Piper Sandler | $85 → $88 | Maintains | Neutral |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Edwards Lifesciences (EW)?
El último precio objetivo de Edwards Lifesciences (NYSE:EW) fue comunicado por Truist Securities el noviembre 3, 2025. La firma de analistas fijó un precio objetivo para $90.00 que espera EW a rise dentro de 12 meses (un posible 4.29% upside). 56 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Edwards Lifesciences (EW)?
La última calificación de analistas para Edwards Lifesciences (NYSE:EW) fue proporcionada por Truist Securities, y Edwards Lifesciences mantuvo su hold calificación.
¿Cuándo se produjo la última revisión al alza de Edwards Lifesciences (EW)?
La última revisión al alza de Edwards Lifesciences Corp se produjo en octubre 29, 2025, cuando Wolfe Research elevó su precio objetivo a N/A. Wolfe Research anteriormente tenía an underperform para Edwards Lifesciences Corp.
¿Cuándo fue la última revisión a la baja de Edwards Lifesciences (EW)?
La última revisión a la baja de Edwards Lifesciences Corp se produjo en octubre 8, 2025, cuando Oppenheimer cambió su precio objetivo de N/A a N/A para Edwards Lifesciences Corp.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Edwards Lifesciences (EW)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Edwards Lifesciences, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Edwards Lifesciences se registró el noviembre 3, 2025, por lo que la próxima calificación estará disponible en torno al noviembre 3, 2026.
¿Es correcta la calificación de los analistas sobre Edwards Lifesciences (EW)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Edwards Lifesciences (EW) fue un mantuvo con un precio objetivo de $87.00 a $90.00. El precio actual al que cotiza Edwards Lifesciences (EW) es de $86.30, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.